CytomX Therapeutics (CTMX) Aktievy
CytomX Therapeutics, Inc. är ett onkologifokuserat biofarmaceutiskt företag som fokuserar på att utveckla potenta biologiska läkemedel avsedda att behandla tumörens mikromiljö. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
CTMX Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CytomX Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$3.01 |
| 52 veckors högsta | US$8.21 |
| 52 veckors lägsta | US$1.72 |
| Beta | 2.09 |
| 1 månads förändring | -16.62% |
| 3 månaders förändring | -55.41% |
| 1 års förändring | 9.45% |
| 3 års förändring | 94.19% |
| 5 års förändring | -58.08% |
| Förändring sedan börsintroduktionen | -76.67% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 11
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Analysts have nudged their average price target for CytomX Therapeutics higher into the mid teens, citing stronger conviction in the late line colorectal cancer potential of varsetatug masetecan and CX-2051 following Phase 1 expansion data and a series of recent target increases that include moves to $11, $12 and $17. Analyst Commentary Recent research updates on CytomX Therapeutics cluster around two themes, the commercial potential of varsetatug masetecan and CX-2051 in colorectal and colon cancer, and how much risk is acceptable at current valuation levels.Uppdatering av berättelse • May 28
CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects
Analysts have trimmed their average price target for CytomX Therapeutics by about $1.22, citing updated expectations for revenue growth, profitability and future P/E. They still point to supportive recent research that highlights the potential of Varseta-M and CX-2051 in colorectal cancer.Seeking Alpha • May 26
CytomX Therapeutics: Cashed Up With Catalysts Ahead
Summary In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand. CTMX should report updated data from its monotherapy work with Varseta-M in H2'26, and could even begin a registrational trial in H1'27. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Jun 11
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Analysts have nudged their average price target for CytomX Therapeutics higher into the mid teens, citing stronger conviction in the late line colorectal cancer potential of varsetatug masetecan and CX-2051 following Phase 1 expansion data and a series of recent target increases that include moves to $11, $12 and $17. Analyst Commentary Recent research updates on CytomX Therapeutics cluster around two themes, the commercial potential of varsetatug masetecan and CX-2051 in colorectal and colon cancer, and how much risk is acceptable at current valuation levels.Uppdatering av berättelse • May 28
CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects
Analysts have trimmed their average price target for CytomX Therapeutics by about $1.22, citing updated expectations for revenue growth, profitability and future P/E. They still point to supportive recent research that highlights the potential of Varseta-M and CX-2051 in colorectal cancer.Seeking Alpha • May 26
CytomX Therapeutics: Cashed Up With Catalysts Ahead
Summary In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand. CTMX should report updated data from its monotherapy work with Varseta-M in H2'26, and could even begin a registrational trial in H1'27. Read the full article on Seeking AlphaAnalysartikel • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...Analysartikel • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...Uppdatering av berättelse • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.Uppdatering av berättelse • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.Uppdatering av berättelse • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Uppdatering av berättelse • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.
Uppdatering av berättelse • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.Uppdatering av berättelse • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.Analysartikel • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...Uppdatering av berättelse • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.Uppdatering av berättelse • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.Uppdatering av berättelse • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.Uppdatering av berättelse • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.Uppdatering av berättelse • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.Analysartikel • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...Uppdatering av berättelse • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.Uppdatering av berättelse • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.Analysartikel • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analysartikel • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...Uppdatering av berättelse • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.Analysartikel • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analysartikel • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...Analysartikel • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
Ny berättelse • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.Analysartikel • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...Analysartikel • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...Analysartikel • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Seeking Alpha • Jul 15
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Summary CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects. Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development. The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs. CTMX has a short cash runway and potential dilution risks in the next few years. I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist. Read the full article on Seeking AlphaAnalysartikel • Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
The CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has fared very poorly over the last month, falling by a...Aktieägarnas avkastning
| CTMX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 0.3% | 1.7% | 0.5% |
| 1Y | 9.5% | 27.8% | 23.5% |
Avkastning vs industri: CTMX presterade sämre än US Biotechs branschen som gav 27.7 % under det senaste året.
Avkastning vs Marknaden: CTMX presterade sämre än US marknaden som gav 24.5 % under det senaste året.
Prisvolatilitet
| CTMX volatility | |
|---|---|
| CTMX Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: CTMX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: CTMX s veckovolatilitet ( 16% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 69 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc. är ett onkologifokuserat biofarmaceutiskt företag som fokuserar på att utveckla potenta biologiska läkemedel avsedda för behandling av tumörens mikromiljö. Företaget använder plattformstekniken för villkorad aktivering för forskning och utveckling av biologiska läkemedel inom onkologi, vilket omfattar validering av mål för antikropps-läkemedelskonjugat (ADC), öppnande av terapeutiska fönster för nya T-cellsengagerare (TCE) inriktade på solida tumörer och ökning av det terapeutiska indexet för immunmodulatorer, såsom cytokiner, samt PROBODY-plattformen för preklinisk forskning inom områden utanför onkologi. Företaget utvecklar också CX-904, en bispecifik antikropp som engagerar T-celler och riktar sig mot EGFR (epidermal tillväxtfaktorreceptor) på tumörceller och CD3-receptorn på T-celler, CX-2051, en villkorligt aktiverad ADC för att optimera det terapeutiska indexet för EpCAM-uttryckande epiteliala cancerformer, inklusive kolorektalcancer, och CX-801, en PROBODY-cytokin med interferon alfa-2b.
CytomX Therapeutics, Inc. Sammanfattning av grunderna
| CTMX grundläggande statistik | |
|---|---|
| Börsvärde | US$655.29m |
| Vinst(TTM) | -US$62.14m |
| Intäkter(TTM) | US$35.54m |
18.4x
P/S-förhållande-10.5x
P/E-förhållandeÄr CTMX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CTMX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$35.54m |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$35.54m |
| Övriga kostnader | US$97.69m |
| Intäkter | -US$62.14m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.29 |
| Bruttomarginal | 100.00% |
| Nettovinstmarginal | -174.84% |
| Skuld/egenkapitalförhållande | 0% |
Hur har CTMX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/14 04:17 |
| Aktiekurs vid dagens slut | 2026/06/12 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
CytomX Therapeutics, Inc. bevakas av 19 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |